Genital Diseases, Female  >>  saracatinib (AZD0530)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
saracatinib (AZD0530) / AstraZeneca
NCT00659360: AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma

Completed
2
17
US, Canada
saracatinib, AZD0530
National Cancer Institute (NCI)
Adult Fibrosarcoma, Adult Leiomyosarcoma, Adult Liposarcoma, Adult Malignant Fibrous Histiocytoma, Adult Rhabdomyosarcoma, Dermatofibrosarcoma Protuberans, Endometrial Stromal Sarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Uterine Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage III Uterine Sarcoma, Stage IV Adult Soft Tissue Sarcoma, Stage IV Uterine Sarcoma, Uterine Carcinosarcoma, Uterine Leiomyosarcoma
01/09
11/12
OVERT-1, NCT00610714 / 2007-005325-30: AZD0530 Phase II Study in Patients With Advanced Ovarian Cancer

Completed
2
211
Canada, Europe, RoW
AZD0530, Carboplatin, CBDCA, Paraplatin®, Paclitaxel, Taxol®
AstraZeneca
Ovarian Neoplasms, Ovarian Cancer
08/09
01/12

Download Options